NCT04871633View on ClinicalTrials.gov

Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

November 15, 2020

Study Completion Date

December 30, 2020

Conditions
COVID-19
Interventions
DRUG

Remdesivir

Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days

DRUG

Conventional

IV Steroids Antibiotics

Trial Locations (1)

54000

Mayo Hospital, Lahore

All Listed Sponsors
lead

King Edward Medical University

OTHER

NCT04871633 - Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore | Biotech Hunter | Biotech Hunter